Breaking News

Friday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Syndicate
First Wave BioPharma files to sell 12.5M shares of common stock for holders  17:08
12/02/22
12/02
17:08
12/02/22
17:08
FWBI

First Wave BioPharma

/

+

 
ShowHide Related Items >><<
FWBI First Wave BioPharma
/

+

FWBI First Wave BioPharma
/

+

12/01/22 H.C. Wainwright
First Wave BioPharma price target lowered to $4 from $8 at H.C. Wainwright
05/26/22 Roth Capital
First Wave BioPharma price target lowered to $9 from $20 at Roth Capital
12/07/21 Maxim
First Wave BioPharma downgraded to Hold from Buy at Maxim
12/07/21 Maxim
First Wave BioPharma downgraded to Hold from Buy at Maxim
Recommendations
NextCure price target lowered to $1 from $5 at BofA » 12:03
12/02/22
12/02
12:03
12/02/22
12:03
NXTC

NextCure

$1.39 /

+ (+0.00%)

BofA analyst Alec…

BofA analyst Alec Stranahan lowered the firm's price target on NextCure to $1 from $5 and keeps an Underperform rating on the shares. The firm's bearish thesis is inflated by the discontinuation of NC318, lack of actionable data from SITC, and the difficult setup for NC410 given the lack of clinical validation of FIND-10, Stranahan tells investors in a research note.

ShowHide Related Items >><<
NXTC NextCure
$1.39 /

+ (+0.00%)

NXTC NextCure
$1.39 /

+ (+0.00%)

11/04/22 Ladenburg
Ladenburg downgrades NextCure after NC318 development discontinuation
11/04/22 Ladenburg
NextCure downgraded to Neutral from Buy at Ladenburg
11/03/22 Piper Sandler
NextCure price target lowered to $6 from $13 at Piper Sandler
08/23/22 Truist
NextCure price target lowered to $15 from $19 at Truist
NXTC NextCure
$1.39 /

+ (+0.00%)

Thursday
Conference/Events
Assertio Holdings management to meet with Lake Street » 12:52
12/01/22
12/01
12:52
12/01/22
12:52
ASRT

Assertio Holdings

$3.02 /

-0.065 (-2.11%)

Meetings to be held with…

Meetings to be held with President & CEO Peisert and CFO Schwichtenberg in Milwaukee, WI on December 7 and in Minneapolis, MN on December 8 hosted by Lake Street.

ShowHide Related Items >><<
ASRT Assertio Holdings
$3.02 /

-0.065 (-2.11%)

ASRT Assertio Holdings
$3.02 /

-0.065 (-2.11%)

11/07/22 Lake Street
Assertio Holdings initiated with a Buy at Lake Street
05/18/22 BWS Financial
Assertio Holdings initiated with a Buy at BWS Financial
ASRT Assertio Holdings
$3.02 /

-0.065 (-2.11%)

ASRT Assertio Holdings
$3.02 /

-0.065 (-2.11%)

Recommendations
First Wave BioPharma price target lowered to $4 from $8 at H.C. Wainwright » 12:00
12/01/22
12/01
12:00
12/01/22
12:00
FWBI

First Wave BioPharma

/

+

H.C. Wainwright analyst…

H.C. Wainwright analyst Yi Chen lowered the firm's price target on First Wave BioPharma to $4 from $8 and keeps a Buy rating on the shares. Assuming 18.3M shares outstanding at the end of 2023, this yields a value of approximately $4, Chen tells investors in a research note.

ShowHide Related Items >><<
FWBI First Wave BioPharma
/

+

FWBI First Wave BioPharma
/

+

05/26/22 Roth Capital
First Wave BioPharma price target lowered to $9 from $20 at Roth Capital
12/07/21 Maxim
First Wave BioPharma downgraded to Hold from Buy at Maxim
12/07/21 Maxim
First Wave BioPharma downgraded to Hold from Buy at Maxim
On The Fly
Here's What You Missed in Cannabis This Week » 10:47
12/01/22
12/01
10:47
12/01/22
10:47
HITI

High Tide

$1.85 /

-0.02 (-1.07%)

, IGC

India Globalization Capital

/

+

, CGC

Canopy Growth

$3.66 /

+0.03 (+0.83%)

, ETRGF

Entourage Health

/

+

, PLNHF

Planet 13 Holdings

$1.35 /

-0.02 (-1.46%)

, GNLN

Greenlane

/

+

, ACB

Aurora Cannabis

$1.28 /

+0.01 (+0.79%)

, CVSI

CV Sciences

/

+

, CRON

Cronos Group

$3.19 /

+0.085 (+2.74%)

, CTST

CannTrust

/

+

, CANN

General Cannabis

/

+

, GDNSF

Goodness Growth

/

+

, GTBIF

Green Thumb Industries

$13.00 /

+0.3 (+2.36%)

, TLRY

Tilray

$3.93 /

+0.08 (+2.08%)

, TCNNF

Trulieve Cannabis

$12.89 /

-0.07 (-0.54%)

, ZYNE

Zynerba

/

+

, RLMD

Relmada Therapeutics

$4.69 /

+0.05 (+1.08%)

, ATAI

Atai Life Sciences

$3.36 /

-0.15 (-4.27%)

, CMPS

Compass Pathways

$10.17 /

-0.15 (-1.45%)

In this week's "Rising…

ShowHide Related Items >><<
ZYNE Zynerba
/

+

TLRY Tilray
$3.93 /

+0.08 (+2.08%)

TCNNF Trulieve Cannabis
$12.89 /

-0.07 (-0.54%)

RLMD Relmada Therapeutics
$4.69 /

+0.05 (+1.08%)

PLNHF Planet 13 Holdings
$1.35 /

-0.02 (-1.46%)

IGC India Globalization Capital
/

+

HITI High Tide
$1.85 /

-0.02 (-1.07%)

GTBIF Green Thumb Industries
$13.00 /

+0.3 (+2.36%)

GNLN Greenlane
/

+

GDNSF Goodness Growth
/

+

ETRGF Entourage Health
/

+

CVSI CV Sciences
/

+

CRON Cronos Group
$3.19 /

+0.085 (+2.74%)

CMPS Compass Pathways
$10.17 /

-0.15 (-1.45%)

CGC Canopy Growth
$3.66 /

+0.03 (+0.83%)

CANN General Cannabis
/

+

ATAI Atai Life Sciences
$3.36 /

-0.15 (-4.27%)

ACB Aurora Cannabis
$1.28 /

+0.01 (+0.79%)

HITI High Tide
$1.85 /

-0.02 (-1.07%)

01/31/22 Desjardins
High Tide price target lowered to C$11.50 from C$13.50 at Desjardins
IGC India Globalization Capital
/

+

11/09/22 Bernstein
Two more states legalize cannabis, $3B added to TAM, says Bernstein
04/01/22 Alliance Global Partners
Senate remains the hurdle for MORE Act, says Alliance Global Partners
CGC Canopy Growth
$3.66 /

+0.03 (+0.83%)

11/07/22 Canaccord
Canopy Growth price target raised to C$5 from C$4.25 at Canaccord
11/01/22 Bernstein
Bernstein starts Canopy Growth at Underperform, sees equity raise
11/01/22 Bernstein
Canopy Growth initiated with an Underperform at Bernstein
ETRGF Entourage Health
/

+

06/02/22 Canaccord
Entourage Health downgraded to Hold from Speculative Buy at Canaccord
PLNHF Planet 13 Holdings
$1.35 /

-0.02 (-1.46%)

GNLN Greenlane
/

+

11/16/22 Alliance Global Partners
Greenlane price target lowered to $2 from $6 at Alliance Global Partners
11/01/22 Roth Capital
Greenlane downgraded to Neutral from Buy at Roth Capital
08/17/22 Alliance Global Partners
Greenlane price target raised to $6 from $1.50 at Alliance Global Partners
08/17/22 Canaccord
Greenlane price target lowered to $5 from $20 at Canaccord
ACB Aurora Cannabis
$1.28 /

+0.01 (+0.79%)

10/07/22 Stifel
Cannabis stocks could rise about three times in near-term, says Stifel
09/21/22 Canaccord
Aurora Cannabis upgraded to Hold from Sell at Canaccord
09/21/22 Piper Sandler
Aurora Cannabis price target lowered to $3 from $4 at Piper Sandler
CVSI CV Sciences
/

+

CRON Cronos Group
$3.19 /

+0.085 (+2.74%)

11/08/22 Canaccord
Cronos Group price target lowered to C$4.75 from C$5 at Canaccord
11/01/22 Bernstein
Cronos started with Market Perform on limited visibility at Bernstein
11/01/22 Bernstein
Cronos Group initiated with a Market Perform at Bernstein
CTST CannTrust
/

+

CANN General Cannabis
/

+

GDNSF Goodness Growth
/

+

11/16/22 Canaccord
Goodness Growth price target lowered to C$0.85 from C$1 at Canaccord
10/14/22 Alliance Global Partners
Verano Holdings price target lowered to C$12 from C$16 at Alliance Global
05/12/22 Canaccord
Goodness Growth price target lowered to C$3.50 from C$4 at Canaccord
GTBIF Green Thumb Industries
$13.00 /

+0.3 (+2.36%)

12/01/22 Wedbush
Wedbush starts Green Thumb with Outperform, names top cannabis pick
12/01/22 Wedbush
Green Thumb Industries initiated with an Outperform at Wedbush
11/03/22 Stifel
Green Thumb Industries price target raised to C$31 from C$30.50 at Stifel
TLRY Tilray
$3.93 /

+0.08 (+2.08%)

11/01/22 Bernstein
Tilray initiated with Market Perform, $3.90 target at Bernstein
11/01/22 Bernstein
Tilray initiated with a Market Perform at Bernstein
TCNNF Trulieve Cannabis
$12.89 /

-0.07 (-0.54%)

12/01/22 Wedbush
Wedbush starts Trulieve with Outperform on broadening reach
12/01/22 Wedbush
Trulieve Cannabis initiated with an Outperform at Wedbush
11/10/22 Canaccord
Trulieve Cannabis price target lowered to C$50 from C$54 at Canaccord
ZYNE Zynerba
/

+

06/23/22 Canaccord
Zynerba price target raised to $11 from $9 at Canaccord
RLMD Relmada Therapeutics
$4.69 /

+0.05 (+1.08%)

11/11/22 SVB Securities
Relmada 'still has a chance' for positive depression data, says SVB
10/14/22 BofA
Axsome shares could react positively to Relmada trial failure, says BofA
10/14/22 Goldman Sachs
Relmada Therapeutics downgraded to Neutral from Buy at Goldman Sachs
10/14/22 Truist
Relmada Therapeutics downgraded to Hold from Buy at Truist
ATAI Atai Life Sciences
$3.36 /

-0.15 (-4.27%)

11/01/22 Loop Capital
Atai Life Sciences initiated with a Buy at Loop Capital
09/01/22 Citi
Atai Life Sciences price target lowered to $20 from $22 at Citi
05/17/22 Citi
Atai Life Sciences price target lowered to $22 from $26 at Citi
04/01/22 Canaccord
Atai Life Sciences price target lowered to $27 from $28 at Canaccord
CMPS Compass Pathways
$10.17 /

-0.15 (-1.45%)

11/01/22 Loop Capital
Compass Pathways initiated with a Buy at Loop Capital
10/13/22 Oppenheimer
Compass Pathways price target lowered to $55 from $65 at Oppenheimer
10/13/22 Canaccord
Compass Pathways price target lowered to $50 from $78 at Canaccord
08/05/22 Cantor Fitzgerald
Compass Pathways price target lowered to $35 from $58 at Cantor Fitzgerald
ZYNE Zynerba
/

+

TLRY Tilray
$3.93 /

+0.08 (+2.08%)

RLMD Relmada Therapeutics
$4.69 /

+0.05 (+1.08%)

HITI High Tide
$1.85 /

-0.02 (-1.07%)

GNLN Greenlane
/

+

ETRGF Entourage Health
/

+

CRON Cronos Group
$3.19 /

+0.085 (+2.74%)

CMPS Compass Pathways
$10.17 /

-0.15 (-1.45%)

CGC Canopy Growth
$3.66 /

+0.03 (+0.83%)

ATAI Atai Life Sciences
$3.36 /

-0.15 (-4.27%)

ACB Aurora Cannabis
$1.28 /

+0.01 (+0.79%)

  • 27
    May
  • 09
    Dec
PLNHF Planet 13 Holdings
$1.35 /

-0.02 (-1.46%)

IGC India Globalization Capital
/

+

HITI High Tide
$1.85 /

-0.02 (-1.07%)

ETRGF Entourage Health
/

+

CGC Canopy Growth
$3.66 /

+0.03 (+0.83%)

ACB Aurora Cannabis
$1.28 /

+0.01 (+0.79%)

TLRY Tilray
$3.93 /

+0.08 (+2.08%)

RLMD Relmada Therapeutics
$4.69 /

+0.05 (+1.08%)

CGC Canopy Growth
$3.66 /

+0.03 (+0.83%)

ACB Aurora Cannabis
$1.28 /

+0.01 (+0.79%)

Hot Stocks
Nuvectis Pharma announces FDA granted FTD to NXP800 » 08:04
12/01/22
12/01
08:04
12/01/22
08:04
NVCT

Nuvectis Pharma

$7.17 /

+ (+0.00%)

Nuvectis Pharma announced…

Nuvectis Pharma announced that the U.S. Food and Drug Administration, FDA, has granted Fast Track Designation, FTD, to NXP800 for the treatment of platinum-resistant, ARID1A-mutated ovarian carcinoma. "We are very pleased with the FDA's decision to grant Fast Track Designation to NXP800 for the treatment of platinum-resistant, ARID1A-mutated ovarian carcinoma, which underscores the potential of NXP800 to address this serious condition of unmet medical need," said Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis. Mr. Bentsur added, "We remain focused on our mission of developing novel treatments for severe oncological conditions, and we believe that with our pipeline of targeted-therapy drug candidates and experienced development team we are well positioned to achieve our goals."

ShowHide Related Items >><<
NVCT Nuvectis Pharma
$7.17 /

+ (+0.00%)

NVCT Nuvectis Pharma
$7.17 /

+ (+0.00%)

07/13/22 Ladenburg
Nuvectis Pharma initiated with a Buy at Ladenburg
05/10/22 H.C. Wainwright
Nuvectis Pharma price target raised to $21 from $14 at H.C. Wainwright
03/02/22 H.C. Wainwright
Nuvectis Pharma initiated with a Buy at H.C. Wainwright
NVCT Nuvectis Pharma
$7.17 /

+ (+0.00%)

  • 04
    Feb
Wednesday
Hot Stocks
First Wave files IND for microgranule delivery formulation of adrulipase » 07:10
11/30/22
11/30
07:10
11/30/22
07:10
FWBI

First Wave BioPharma

/

+

First Wave BioPharma…

First Wave BioPharma announced that it has submitted an Investigational New Drug, IND, application seeking authorization from the U.S. Food and Drug Administration, FDA, to evaluate an enhanced enteric microgranule delivery formulation of adrulipase as a treatment for exocrine pancreatic insufficiency associated with cystic fibrosis and chronic pancreatitis in human clinical trials. Upon IND clearance, First Wave expects to initiate a Phase 2 trial at the beginning of 2023. "Filing the IND is an important step in enabling First Wave to initiate the planned Phase 2 trial of our new formulation for adrulipase," said James Sapirstein, President and CEO of First Wave BioPharma. "If the FDA grants authorization in the next 30 days, we expect to start the study in early 2023 with topline data anticipated towards the end of the first half of 2023. We anticipate that these near-term clinical milestones will reinforce our previous research, such as data recently presented at AAPS 2022 showing the new adrulipase formulation can deliver the drug in the intended area of the gastrointestinal tract, where it can provide the desired therapeutic effect," Sapirstein added. "We look forward to investigating this potential in a Phase 2 clinical trial and the opportunity to one day provide therapeutic relief to patients with exocrine pancreatic insufficiency associated with cystic fibrosis and chronic pancreatitis."

ShowHide Related Items >><<
FWBI First Wave BioPharma
/

+

FWBI First Wave BioPharma
/

+

05/26/22 Roth Capital
First Wave BioPharma price target lowered to $9 from $20 at Roth Capital
12/07/21 Maxim
First Wave BioPharma downgraded to Hold from Buy at Maxim
12/07/21 Maxim
First Wave BioPharma downgraded to Hold from Buy at Maxim
Tuesday
Hot Stocks
Atai Life Sciences names Sahil Kirpekar Chief Business Officer » 07:05
11/29/22
11/29
07:05
11/29/22
07:05
ATAI

Atai Life Sciences

$3.00 /

-0.085 (-2.76%)

Atai Life Sciences…

Atai Life Sciences appointed Sahil Kirpekar to serve as the company's Chief Business Officer, effective immediately. Kirpekar joins atai after more than eight years at Otsuka Pharmaceutical, most recently as the Head of Business Development and Co-chair of the Global Business Development Committee. Prior to Otsuka, Kirpekar built and executed on commercial and market access strategies for biopharmaceutical companies globally as a strategy consultant at Double Helix Consulting. He also served as a market analyst for the World Health Organization and has co-founded a company building a drug delivery device focused on adherence.

ShowHide Related Items >><<
ATAI Atai Life Sciences
$3.00 /

-0.085 (-2.76%)

ATAI Atai Life Sciences
$3.00 /

-0.085 (-2.76%)

11/01/22 Loop Capital
Atai Life Sciences initiated with a Buy at Loop Capital
09/01/22 Citi
Atai Life Sciences price target lowered to $20 from $22 at Citi
05/17/22 Citi
Atai Life Sciences price target lowered to $22 from $26 at Citi
04/01/22 Canaccord
Atai Life Sciences price target lowered to $27 from $28 at Canaccord
ATAI Atai Life Sciences
$3.00 /

-0.085 (-2.76%)

ATAI Atai Life Sciences
$3.00 /

-0.085 (-2.76%)

Monday
Recommendations
Assure Holdings price target lowered to $3 from $5.50 at Roth Capital » 14:55
11/28/22
11/28
14:55
11/28/22
14:55
IONM

Assure Holdings

/

+

Roth Capital analyst…

Roth Capital analyst Scott Henry lowered the firm's price target on Assure Holdings to $3 from $5.50 and keeps a Buy rating on the shares. The analyst notes the company reported Q3 results that were below expectations, with gross revenues of $6.2M trailing the consensus target of $7.4M as the company exited less profitable markets. The company also lowered case targets for 2022 to 21K-22K from 25K, and revenue per case was also declining due to challenging reimbursement environments, Henry adds.

ShowHide Related Items >><<
IONM Assure Holdings
/

+

IONM Assure Holdings
/

+

06/14/22 Roth Capital
Assure Holdings initiated with a Buy at Roth Capital
05/18/22 Benchmark
Assure Holdings price target lowered to $6 from $9 at Benchmark
04/05/22 Benchmark
Assure Holdings initiated with a Speculative Buy at Benchmark
IONM Assure Holdings
/

+

  • 22
    Aug
IONM Assure Holdings
/

+

Hot Stocks
Panbela Therapeutics enrolls first patients in Europe for ASPIRE trial » 09:18
11/28/22
11/28
09:18
11/28/22
09:18
PBLA

Panbela Therapeutics

/

+

Panbela Therapeutics…

Panbela Therapeutics announced its first patients enrolled in Europe for its ASPIRE global clinical trial in the first-line treatment of metastatic pancreatic cancer. ASPIRE is a global randomized, double-blind placebo-controlled clinical trial to evaluate ivospemin in combination with gemcitabine and nab-Paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma. With approximately 95 sites planned throughout the United States, Europe, Australia, and South Korea, Panbela is continuing to focus on site initiation and enrollment in order to ultimately deliver a more effective treatment for pancreatic cancer, a deadly disease with few treatment options. The Company expects that a significant number of global sites will be open by year-end with the full complement of sites open by early-mid 2023.

ShowHide Related Items >><<
PBLA Panbela Therapeutics
/

+

PBLA Panbela Therapeutics
/

+

10/12/22 Maxim
Panbela Therapeutics downgraded to Hold from Buy at Maxim
02/23/22 Craig-Hallum
Panbela Therapeutics price target raised to $13 from $9 at Craig-Hallum

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.